Roche to Introduce ATR Inhibitor RP-3500 for $1.2 Billion
On June 1, Repare Therapeutics announced that it has entered into a global license and collaboration agreement with Roche for the development and commercialization of camonsertib (RP-3500).
Under the agreement, Roche will undertake the development of camonsertib, with the potential to expand development into other oncology and multiple combination studies. Repare will receive an upfront payment of $125 million and is eligible to receive up to $1.2 billion in potential development, regulatory, commercial and sales milestones, as well as royalties on global net product sales.
Looking for chemical products? Let suppliers reach out to you!
You May Interested In
β-Nicotinamide Adenine Dinucleotide High Quality NAD+ CAS 53-84-9 Exclusive Production Factory CAS NO.53-84-9
$75/UNIT FOB
Semax CAS 80714-61-0 High Quality Semax 10mg Fast Delivery Raw Powder Weight Loss Peptide
$100/UNIT FOB
2026-07-02
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Lonza acquires Roche US biologics facility for $1.2 billion
-
Lonza acquires biologics plant from Roche for $1.2 billion
-
Roche Acquires Carmot for $3.1 Billion to Enter Obesity Drug Market
-
Aβ monoclonal antibody is broken again, Alzheimer's disease new drug research and development is a long way, who can break the deadlock?
-
Roche's Next-generation C5 Complement Inhibitor Crovalimab Successfully Completed Phase III Study in China
-
Roche's TIGIT Monoclonal Antibody Collapses Again, And A Large Number of Domestic Biopharmaceutical Companies are Deployed
-
Roche's Q1 Performance Increases by 10%, And Total Revenue for the Year May Slow Down Due to COVID-19, Biosimilar Competition
-
Roche's Potential 'First-in-class' Bispecific Therapy Wins EU CHMP Support
-
Novartis has the most new drugs approved, and Roche's new drugs have the highest value!
-
Roche's 2020 annual report is released, sales of innovative drugs surge
Recommend Reading
-
NHU and Sinopec Advance Liquid Methionine Project
-
Merck to Lay Off 150 Workers at US Gardasil Plant Amid Sales Weakness
-
FDA Clears Sanofi’s Wayrilz (rilzabrutinib) for Adult ITP; U.S. Launch in September
-
Aficamten Beats Metoprolol in Obstructive HCM, Strengthening Case Ahead of FDA Decision
-
AstraZeneca Targets Year-End Filing for Novel Hypertension Drug Baxdrostat
-
Market Performance Balanced, PC Holds Steady Before the Festival
-
“Amputation or Strategic Retreat?”: Shell’s Six-Year Chemical Losses and the Quiet Unwinding of an Empire
-
Methanol Market Shows Narrow Fluctuations in China
-
February 10 Isopropanol Market Remains Stable in China
-
Insufficient Support, n-Butanol Market Continues to Decline in China